Abacavir sulfate, Lamivudine and Zidovudine

DRUG6 trials

Sponsors

Glaxo Wellcome, GlaxoSmithKline, National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

HIV InfectionsLipodystrophy

Phase 2

Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

CompletedNCT00021463

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections, Lipodystrophy

Target: 342Updated: 2011-02-28

Increasing HAART-Induced Immune Restoration With Cyclosporine

CompletedNCT00031070

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2006-12-31Target: 40Updated: 2015-03-09

Phase 3

Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir)

Glaxo WellcomeHIV Infections

Target: 230Updated: 2005-06-24

Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection

CompletedNCT00013520

National Institute of Allergy and Infectious Diseases (NIAID)HIV Infections

End: 2005-06-30Target: 1125Updated: 2012-05-21

Phase 4

A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults

CompletedNCT00004585

Glaxo WellcomeHIV Infections

Start: 1999-10-31Target: 40Updated: 2005-06-24

Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

GlaxoSmithKlineHIV Infections

Start: 2001-02-28Target: 400Updated: 2005-06-24

Related Papers

Association between efavirenz as initial therapy for HIV-1 infection and increased risk for suicidal ideation or attempted or completed suicide: an analysis of trial data.

2014-07-01147 citations

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

2010-03-01152 citations

Substitution of nevirapine because of efavirenz toxicity in AIDS clinical trials group A5095.

2010-03-0118 citations